A Faster Track for Myeloma Treatments?

Draft guidance elevates MRD and complete response, clearing a faster regulatory path for new multiple myeloma therapies

12 Feb 2026

The FDA has made a move that could reshape how multiple myeloma drugs reach the market.

In January 2026, the agency issued draft guidance endorsing minimal residual disease, or MRD, and complete response as primary endpoints for accelerated approval. The decision signals a clear shift toward earlier measures of efficacy and away from waiting years for definitive survival data.

For patients and drugmakers alike, that matters.

MRD detects microscopic traces of cancer left behind after treatment. Using sensitive tools such as next generation sequencing or flow cytometry, clinicians can determine whether a patient has achieved MRD negativity. When that milestone follows a complete response, studies show patients are more likely to stay in remission longer.

By recognizing MRD negativity as a meaningful surrogate endpoint, the FDA is opening the door to faster approvals based on earlier signals of benefit. Sponsors no longer need to rely solely on overall survival data, which can take years to mature.

The flexibility comes with guardrails. Accelerated approvals will still hinge on confirmatory trials that measure traditional endpoints such as progression free survival or overall survival. If those studies fail to verify long term benefit, the agency can withdraw the drug.

Even so, the regulatory tone has shifted.

Developers can now design trials that incorporate MRD from the outset, align biomarker strategies with agency expectations, and potentially reduce development risk and cost. Early discussions with regulators about trial design and assay validation will be crucial.

The implications stretch beyond myeloma. The guidance reinforces a broader embrace of biomarker driven development across oncology. Companies investing in precision diagnostics and adaptive trial designs may find a more receptive climate.

Caution remains. MRD may not predict outcomes equally across every subgroup, and evidence standards remain high.

Still, the direction is clear. By elevating MRD and complete response as actionable endpoints, the FDA is nudging blood cancer research into a faster lane. For patients waiting on better therapies, that shift cannot come soon enough.